X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7967) 7967
Newspaper Article (394) 394
Newsletter (204) 204
Magazine Article (45) 45
Dissertation (23) 23
Book Chapter (13) 13
Trade Publication Article (7) 7
Book / eBook (6) 6
Web Resource (5) 5
Transcript (4) 4
Government Document (1) 1
Publication (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (5023) 5023
humans (3610) 3610
male (3270) 3270
venom (3222) 3222
female (1934) 1934
mice (1509) 1509
rats (1443) 1443
pharmacology & pharmacy (1204) 1204
toxicology (1119) 1119
adult (1059) 1059
middle aged (959) 959
immunology (876) 876
research (793) 793
snakes (787) 787
peptides (744) 744
peptides - pharmacology (699) 699
allergy (658) 658
analysis (647) 647
venoms - therapeutic use (617) 617
care and treatment (613) 613
peptides - therapeutic use (607) 607
diabetes mellitus, type 2 - drug therapy (599) 599
bites and stings (594) 594
exenatide (594) 594
venoms - administration & dosage (594) 594
medicine (592) 592
antivenins - therapeutic use (589) 589
peptides - administration & dosage (588) 588
dose-response relationship, drug (585) 585
venoms - pharmacology (574) 574
proteins (554) 554
time factors (536) 536
treatment outcome (528) 528
immunotherapy (527) 527
aged (524) 524
health aspects (520) 520
antivenom (518) 518
adolescent (505) 505
rats, sprague-dawley (502) 502
endocrinology & metabolism (501) 501
glucagon-like peptide-1 (484) 484
hypoglycemic agents - therapeutic use (455) 455
snake bites - therapy (453) 453
child (451) 451
biochemistry & molecular biology (441) 441
research article (435) 435
disease models, animal (432) 432
type 2 diabetes (419) 419
rats, wistar (416) 416
inflammation (412) 412
envenomation (410) 410
diabetes (407) 407
neurosciences (405) 405
hypoglycemic agents - administration & dosage (395) 395
expression (389) 389
toxins (389) 389
antivenins - administration & dosage (387) 387
bee venom (367) 367
complex mixtures (365) 365
exendin-4 (360) 360
studies (347) 347
physiological aspects (344) 344
medicine, general & internal (342) 342
rodents (332) 332
anaphylaxis (330) 330
physiology (325) 325
medicine, research & experimental (321) 321
glucose (319) 319
enzymes (310) 310
venoms (309) 309
abridged index medicus (307) 307
risk factors (301) 301
pain (300) 300
mice, inbred c57bl (298) 298
insulin (297) 297
snake bites (293) 293
apoptosis (290) 290
activation (288) 288
multidisciplinary sciences (283) 283
cell biology (282) 282
rabbits (280) 280
amino acid sequence (275) 275
glycemic control (274) 274
child, preschool (272) 272
snake venom (270) 270
glucagon-like peptide-1 receptor (266) 266
venoms - adverse effects (264) 264
allergies (261) 261
poisonous snakes (261) 261
hypoglycemic agents - pharmacology (260) 260
pharmacology (258) 258
young adult (256) 256
drug administration schedule (251) 251
drug therapy (251) 251
toxicity (246) 246
snake bites - drug therapy (245) 245
tropical medicine (245) 245
science (244) 244
peptides - adverse effects (243) 243
snakebite (243) 243
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8439) 8439
Portuguese (109) 109
German (76) 76
French (63) 63
Japanese (44) 44
Russian (27) 27
Chinese (22) 22
Spanish (18) 18
Italian (8) 8
Swedish (7) 7
Polish (6) 6
Korean (5) 5
Czech (4) 4
Danish (3) 3
Dutch (2) 2
Norwegian (2) 2
Turkish (2) 2
Arabic (1) 1
Croatian (1) 1
Hungarian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9739, pp. 431 - 439
Journal Article
Journal Article
Journal Article
Journal of controlled release, ISSN 0168-3659, 2017, Volume 264, pp. 102 - 111
The blood brain barrier separates the circulating blood from the extracellular fluid in the central nervous system and thus presents an essential obstacle to... 
Brain-targeting | BBB | Biomimetic nanoparticles | Glioma | DCDX | CDX | BARRIER | NANOCARRIERS | CANCER | TUMORS | CHEMISTRY, MULTIDISCIPLINARY | (CDX)-C-D | GLIOBLASTOMA | THERAPY | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | RED-BLOOD-CELLS | ERYTHROCYTE-MEMBRANE | LIGAND | Doxorubicin - therapeutic use | Gold - administration & dosage | Rats, Wistar | Humans | Peptides - pharmacokinetics | Male | Polyethylene Glycols - chemistry | Antineoplastic Agents - therapeutic use | Doxorubicin - chemistry | Antineoplastic Agents - administration & dosage | Brain Neoplasms - metabolism | Peptides - administration & dosage | Drug Delivery Systems | Glioma - metabolism | Biotin - chemistry | Brain - metabolism | Streptavidin - administration & dosage | Snake Venoms | Biotin - administration & dosage | Doxorubicin - administration & dosage | Gold - chemistry | Streptavidin - chemistry | Receptors, Nicotinic - metabolism | Peptides - chemistry | Endothelial Cells - metabolism | Metal Nanoparticles - chemistry | Cells, Cultured | Metal Nanoparticles - therapeutic use | Antineoplastic Agents - chemistry | Brain Neoplasms - drug therapy | Erythrocyte Membrane | Mice, Inbred ICR | Polyethylene Glycols - administration & dosage | Gold - pharmacokinetics | Animals | Metal Nanoparticles - administration & dosage | Mice, Nude | Cell Line, Tumor | Drug Liberation | Gold - therapeutic use | Glioma - drug therapy | Peptides - therapeutic use | Drugs | Drug delivery systems | Peptides | Gliomas | Analysis | Brain tumors | Cell membranes | Vehicles | Anthracyclines | Homeopathy | Materia medica and therapeutics | Nanoparticles | Therapeutics | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 13, pp. 1228 - 1239
Journal Article
Diabetes care, ISSN 1935-5548, 2014, Volume 37, Issue 8, pp. 2159 - 2167
Journal Article
Scientific reports, ISSN 2045-2322, 2016, Volume 6, Issue 1, p. 18904
A meta-analysis was conducted to assess the clinical efficacy and safety of dulaglutide in patients with type 2 diabetes mellitus (T2DM). Medline, Embase,... 
GLYCEMIC CONTROL | LIRAGLUTIDE | TOLERABILITY | MULTIDISCIPLINARY SCIENCES | EXENATIDE | DOUBLE-BLIND | INCRETIN-BASED THERAPIES | GLP-1 ANALOG | MELLITUS | RANDOMIZED CLINICAL-TRIALS | PEPTIDE-1 RECEPTOR AGONISTS | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Body Weight - drug effects | Immunoglobulin Fc Fragments - administration & dosage | Insulin - blood | Metformin - adverse effects | Peptides - administration & dosage | Insulin Glargine - administration & dosage | Hypoglycemic Agents - administration & dosage | Hypoglycemia - physiopathology | Patient Safety | Venoms - administration & dosage | Hypoglycemia - blood | Metformin - administration & dosage | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Sitagliptin Phosphate - administration & dosage | Insulin Glargine - adverse effects | Venoms - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Hypoglycemia - etiology | Liraglutide - adverse effects | Liraglutide - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Sitagliptin Phosphate - adverse effects | Diabetes mellitus | Body weight | Clinical trials | Body weight loss | Diabetes | Metformin | Hypoglycemia | Insulin
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 01/2016, Volume 18, Issue 1, pp. 49 - 55
Journal Article
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 2017, Volume 19, Issue 4, pp. 524 - 536
Aims To compare efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in people with type 2 diabetes. Materials and methods We... 
GLP‐1 analogue | type 2 diabetes | network meta‐analysis | systematic review | network meta-analysis | GLP-1 analogue | GLYCEMIC CONTROL | EXENATIDE TWICE | ONCE-DAILY LIXISENATIDE | OPEN-LABEL | EUROPEAN ASSOCIATION | NETWORK METAANALYSIS | METFORMIN-TREATED PATIENTS | BASAL INSULIN | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Immunoglobulin Fc Fragments - administration & dosage | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Hypoglycemia - chemically induced | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Peptides - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Glucagon | Analysis | Diabetes therapy | Hypoglycemia | Diabetes | Systematic review | Evidence-based medicine
Journal Article